Clinical trial
GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute…
NCT00459212 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00459212 |
|---|---|
| Title | GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia |
| Official title | Phase I and Pharmacodynamic Study of GTI-2040 (NSC 722929, IND 67368) in Acute Leukemias |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Acute Undifferentiated Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13, q22), Adult Acute Myeloid Leukemia With t(15, 17)(q22, q12), Adult Acute Myeloid Leukemia With t(16, 16)(p13, Adult Acute Myeloid Leukemia With t(8 and 11 more |
| Intervention type | Drug, Procedure |
| Interventions | GTI-2040, pharmacological study, laboratory biomarker analysis |
| Enrollment | 24 |
| Start date | Mar 1, 2007 |
| Primary completion | Dec 1, 2010 |
| First posted | Apr 11, 2007 |
| Last update posted | Dec 4, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: